Lantern Pharma Inc.
No enriched coverage for $LTRN in the last 7 days.
No SEC Form 4 filings for $LTRN in the last 30 days.
See all $LTRN insider activity →Lantern Pharma (LTRN) reported Q2 2026 earnings with $7.1M net loss, $7.4M cash, and reduced R&D expenses. LP-300 showed 8.9-month median PFS in L858R patients. The company is advancing LP-184 trials and plans to raise capital for Open Medicine AI, a new AI subsidiary. Management highlighted potential partnerships and cost efficiencies.
Lantern Pharma (LTRN) has a cash runway of about 6 months, with $7.4M in cash and a $14M annual burn rate. While its burn rate decreased 21% year-over-year, the company's burn is high relative to its $30M market cap, raising concerns about its ability to fund operations. The company is debt-free but may need to raise cash soon.
Lantern Pharma Inc. (LTRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EM
Recent LTRN coverage spans financial news and earnings.
Loss narrowed but still sizable; cash position modest; R&D cut may improve runway.
The limited cash runway creates near‑term financing risk and could pressure the stock lower.
New clinical and regulatory datapoints plus a cash position update and an OMAI corporate separation create multiple near-term catalysts for LTRN risk and valuation.
Patent allowance strengthens IP protection around LP-184’s biomarker-driven patient selection, supporting valuation and partnering optionality.
Promotional/visibility item; no new clinical datapoint or regulatory milestone, but reinforces AI-driven pipeline narrative.
alphai scores every news story that mentions LTRN with an AI model for sentiment and relevance, and aggregates insider trades from Lantern Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lantern Pharma (LTRN) reported Q2 2026 earnings with $7.1M net loss, $7.4M cash, and reduced R&D expenses. LP-300 showed 8.9-month median PFS in L858R patients. The company is advancing LP-184 trials and plans to raise capital for Open Medicine AI, a new AI subsidiary. Management highlighted potential partnerships and cost efficiencies.
2 min readLantern Pharma (LTRN) has a cash runway of about 6 months, with $7.4M in cash and a $14M annual burn rate. While its burn rate decreased 21% year-over-year, the company's burn is high relative to its $30M market cap, raising concerns about its ability to fund operations. The company is debt-free but may need to raise cash soon.
2 min readLantern Pharma Inc. (LTRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EM
6 min readLantern Pharma (NASDAQ: LTRN) said the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering patient selection and treatment for ovarian, primary liver, kidney and thyroid cancers using LP-184 (zirdafulven). The allowed claims relate to a three-gene biomarker signature (PTGR1, PTPN14, ASPH). Lantern cited a 45% disease control rate at or above the effective dose in Phase 1a and plans multiple Phase 1b/2 studies in 2026.
3 min readNew to The Street said its Bloomberg Television sponsored program airs May 30 at 6:30 PM ET, featuring interviews with executives across AI, healthcare, fintech, digital assets and commodities. Among guests: YesSmile.ai (AI for dental admin in a $200B market), Lantern Pharma (Zeta for rare cancers), Roadzen (AI for auto insurance), and Gold Royalty Corp. (250+ royalties/streams).
2 min readRedChip Companies will broadcast interviews with Enlivex Therapeutics (Nasdaq: ENLV) and Lantern Pharma (Nasdaq: LTRN) on its "RedChip Small Stocks, Big Money™" show on Bloomberg TV this Saturday, October 4th, at 7 p.m. ET. The interviews will cover Enlivex's positive Phase IIa results for Allocetra™ in knee osteoarthritis and Lantern Pharma's AI and machine learning platform, RADR®, for cancer drug discovery and development. Both companies will discuss their clinical pipelines and future development plans.
2 min readUS-based Lantern Pharma Inc., a company focused on AI-driven precision oncology, has announced the opening of an AI Centre of Excellence and Advanced Agentic Labs in Bengaluru, India. This initiative aims to scale up Lantern's AI platform globally, expanding its computational capacity and technical talent. The center will support both Lantern's internal pipeline and collaborations, enhancing its proprietary RADR® AI platform and accelerating the development of specialized large language models and quantitative models for drug discovery.
3 min readLantern Pharma ( NASDAQ:LTRN ) , a biotech focused on AI-enabled precision oncology, released its earnings for the quarter ended June 30, 2025, on August 13, 2025. Lantern Pharma reported a GAAP net loss per share of ( $0.40 ) in Q2 2025, and marking an improvement from ( $0.46 ) per share ( GAAP ...
2 min readAUSTIN, Texas, July 16, 2025 ( GLOBE NEWSWIRE ) -- via IBN -- Lantern Pharma Inc.
2 min readFDA clears Lantern's IND for LP-184 in Phase 1b/2 trial targeting advanced-stage triple-negative breast cancer. Trial includes LP-184 monotherapy and combo with olaparib for BRCA1/2-altered TNBC in second-line settings.
3 min read
